Physician profile
Michael G Alt
NPI 1740227255
$13,300.86
in general payments reported to CMS, 2019-2025
47 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,582 · 2020: $1,397 · 2021: $2,034 · 2022: $1,712 · 2023: $2,163 · 2024: $2,436 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.71 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,821.51 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $1,172.52 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,057.13 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $983.37 | 2019-2022 | |
| Abbvie INC. | $916.45 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Amgen INC. | $561.06 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $506.57 | 2021-2025 | Rytary, Crexont |
| Alexion Pharmaceuticals, INC. | $488.82 | 2019-2025 | Ultomiris |
| Eisai INC. | $487.42 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $475.98 | 2019-2023 | Ajovy |
| Genzyme Corporation | $393.68 | 2019-2023 | |
| Argenx US, INC. | $379.02 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $314.46 | 2019-2025 | Nuplazid |
| Acorda Therapeutics, INC | $280.52 | 2019-2023 | Inbrija, Ampyra |
| Sk Life Science, INC. | $273.98 | 2021-2025 | Xcopri |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.